title: Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
abstract: We studied the acceptability of tenofovir gel among HIV-infected and uninfected men who were exposed to it during vaginal intercourse. The gel was found to be highly acceptable to most men, the large majority indicating they would probably use it in the future if they were concerned about HIV and the product were available. Men liked the gel's transparency and odorless qualities, although reactions to its viscosity were more varied. Men acknowledged women's rights to self-determination concerning HIV-prevention, yet considered that women's covert use of the product was more acceptable in the context of 'one-night-stands' than in stable relationships, for which dialogue on protection measures was preferred. Restrictions to couples' habitual sexual repertoire and the protocol requirement to use condoms resulted in complaints. Microbicide trials that do not require condom use from men who don't typically use them may provide a more accurate assessment of acceptability. Consistent microbicide use may be contingent on its ease of incorporation into typical sexual practices, type of sexual partnership and contextual issues.
authors.affiliation: HIV Center for Clinical and Behavioral StudiesNew York State Psychiatric Institute, New York, NY 10032, USA. ac72@columbia.edu
authors.forename: Alex
authors.initials: A
authors.lastname: Carballo-Diéguez
authors.forename: Iván C
authors.initials: IC
authors.lastname: Balán
authors.forename: Kathleen
authors.initials: K
authors.lastname: Morrow
authors.forename: Rochelle
authors.initials: R
authors.lastname: Rosen
authors.forename: Joanne E
authors.initials: JE
authors.lastname: Mantell
authors.forename: Fang
authors.initials: F
authors.lastname: Gai
authors.forename: Susie
authors.initials: S
authors.lastname: Hoffman
authors.forename: Lisa
authors.initials: L
authors.lastname: Maslankowski
authors.forename: Wafaa
authors.initials: W
authors.lastname: El-Sadr
authors.forename: Kenneth
authors.initials: K
authors.lastname: Mayer
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000282:Administration, Intravaginal; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D017060:Patient Satisfaction; D012749:Sexually Transmitted Diseases / Q000517:prevention & control; D000068698:Tenofovir; D016896:Treatment Outcome; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D014622:Vaginal Creams, Foams, and Jellies; D000068698:Tenofovir; D000225:Adenine